baqsimi
eli lilly nederland b.v. - glucagon - diabeet mellitus - pankrease hormoonid, hormoonid glycogenolytic - baqsimi on näidustatud ravi raskeid hypoglycaemia täiskasvanutel, noorukitel ja lastel vanuses 4 aastat ja enam, kellel diabeet.
insulin aspart sanofi
sanofi winthrop industrie - aspartinsuliin - diabeet mellitus - diabeetis kasutatavad ravimid - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
kirsty (previously kixelle)
biosimilar collaborations ireland limited - aspartinsuliin - diabeet mellitus - diabeetis kasutatavad ravimid - kirsty is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
truvelog mix 30
sanofi winthrop industrie - aspartinsuliin - diabeet mellitus - diabeetis kasutatavad ravimid - truvelog mix 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above.
inpremzia
baxter holding b.v. - insulin human (rdna) - diabeet mellitus - diabeetis kasutatavad ravimid - inpremzia is indicated for the treatment of diabetes mellitus.
dexdomitor
orion corporation - dexmedetomidine hydrochloride - psühhoeptikumid - dogs; cats - mitte invasiivsed, kergelt kuni mõõdukalt valusad, protseduurid ja uuringud, mis nõuavad koerte ja kasside talitlust, sedatsiooni ja analgeesiat. premedikatsioon kassidel enne indutseerimist ja üldanesteesia säilitamist koos ketamiiniga. suu sedatsioon ja analgeesia koertel, mida kasutatakse koos butorfanooliga meditsiiniliste ja väikeste kirurgiliste protseduuride jaoks. premedikatsioon koertel enne induktsiooni ja üldanesteesia säilitamist.
deep heat rub kreem
colep laupheim gmbh & co. kg - metüülsalitsülaat+levomentool+eukalüptiõli+tärpentiniõli - kreem - 128mg+59,1mg+19,7mg+14,7mg 1g 15g 1tk
byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmoloogilised vahendid - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmoloogilised vahendid - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
segluromet
merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid, metformin hydrochloride - suhkurtõbi, tüüp 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.